Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Abroad (travel likely)RecruitingPHASE2
Conditions
GIST - Gastrointestinal Stromal Tumor · KIT Gene Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Contact: Principal Investigator (Jian Li, MD)
Study leads
Jian Li, MD
Study Chair
Peking University Cancer Hospital & Institute